invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal
invIOs GmbH (“invIOs”), a privately held biotechnology company developing innovative cancer immunotherapies, today announced the publication of new clinical data with its autologous PBMC (peripheral blood mononuclear cell) therapy APN401 in the peer-reviewed journal, Molecular Therapy Oncology.
Read original article on The Medical News →Related news
-
Good News in History, October 16
United Kingdom
-
What went right this week: the good news that matters
United Kingdom
-
Drug-coated balloons offer an alternative to permanent heart stents
United Kingdom
-
Parents know fruit and vegetables are healthy, but many underestimate how much children need
United Kingdom
-
Bisphenol mixtures alter breast tissue development in lab-grown human models
United Kingdom
-
New study could help reduce radiation exposure during cardiac CT scans
United Kingdom
-
Study identifies priority genes for safer prescribing in older Chinese patients
United Kingdom
-
Home delivery boosts fresh produce prescription redemption among older adults
United Kingdom